Subtype
Myoepithelial Tumor
CI-CAN-00001263Explore in graph →
Non-malignant2 active trials5 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001263Explore in graph →
Clinical trials
7 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03600649 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | unknown | Phase 1 | 50 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05266196 |
Data updated 22 days agoSource updated Aug 3, 2026source: clinicaltrials
| A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) |
| unknown |
| Phase 1 / Phase 2 |
| 10 |
| Salarius Pharmaceuticals, LLCINDUSTRY |
| 1 |
| Aug 1, 2023 |
| clinicaltrials |